The Cardiac Arrhythmia Suppression Trial

To the Editor: Some proarrhythmia must be expected with the use of all antiarrhythmic drugs. The results of any antiarrhythmic drug trial should therefore be considered in terms of an antiarrhythmia–proarrhythmia equilibrium, with beneficial outcome being an expression of the extent to which antiarr...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 321; no. 25; pp. 1754 - 1756
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 21.12.1989
Subjects
Aged
Anilides - therapeutic use
Arrhythmias, Cardiac - drug therapy
Encainide
Flecainide - therapeutic use
Humans
Male
Online AccessGet full text

Cover

More Information
Summary:To the Editor: Some proarrhythmia must be expected with the use of all antiarrhythmic drugs. The results of any antiarrhythmic drug trial should therefore be considered in terms of an antiarrhythmia–proarrhythmia equilibrium, with beneficial outcome being an expression of the extent to which antiarrhythmic efficacy exceeds deaths from proarrhythmia. The risk inherent to the study population, provided by mortality figures from the placebo groups, is a major factor in establishing the balance. The Multicenter PostInfarction Research Group study 1 and the Cardiac Arrhythmia Pilot Study 2 provided meticulous preparation for an interventional trial, but the outcome of the Cardiac Arrhythmia Suppression Trial . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJM198912213212510